Cellceutix Corp (CTIX) 1.4600 $CTIX Cellceutix Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellceutix Corp (CTIX) 1.4600 $CTIX

Cellceutix Announces Dismissal of Class Action Lawsuit Filed by Rosen Law Firm
Marketwire Canada - Thu Jun 09, 9:51AM CDT
BEVERLY, MA--(Marketwired - June 09, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that, yesterday, the U.S. District Court for the Southern District of New York granted the Company's motion to dismiss the securities class action lawsuit brought against the Company by a plaintiff represented by the Rosen Law Firm.

Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
Marketwired - Mon Jun 06, 6:01AM CDT
BEVERLY, MA--(Marketwired - June 06, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the study database from the Phase 1 trial of Kevetrin (thioureidobutyronitrile) for advanced solid tumors will be "soft locked" this week. These locked results are the final protocol requirement for the study of Kevetrin in its next clinical trial and will be added to the already prepared documentation for submission to the U.S. Food and Drug Administration ("FDA" in support of the planned Phase 1b/2 trial of Kevetrin in ovarian cancer patients with resistance to platinum-based therapies. Cellceutix is developing Kevetrin under an Orphan Drug designation from the FDA.

Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week
Marketwired - Tue May 31, 6:00AM CDT
BEVERLY, MA--(Marketwired - May 31, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce that the pharmacokinetics (PK) data on the recently completed Phase 2 trial of Prurisol as a novel oral treatment for plaque psoriasis has been received and is starting to be analyzed.

Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis
Marketwire Canada - Thu May 26, 6:01AM CDT
BEVERLY, MA--(Marketwired - May 26, 2016) -  Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today provides additional insight into the successfully completed Phase 2 trial of Prurisol as a new oral therapy for mild to moderate plaque psoriasis.

Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Marketwired - Tue May 24, 9:01AM CDT
BEVERLY, MA--(Marketwired - May 24, 2016) -

Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow
Marketwire Canada - Wed May 11, 8:30AM CDT
BEVERLY, MA--(Marketwired - May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the clinical database for the Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.

Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.06 (+0.16), CBMG: 14.98 (+0.14), OCAT: 8.47 (+0.01), ZBH: 118.08 (+1.60), PFE: 34.46 (+0.24), LLY: 74.18 (+0.32), GSK: 41.70 (+1.37), GLPG: 52.79 (+1.42), AXSM: 6.53 (+0.19), OMER: 10.59 (+0.04), CANF: 2.65 (+0.03), AST: 2.99 (+0.02), AKTX: 14.61 (-0.19)

Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates
Marketwired - Tue Apr 19, 9:30AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that the clinical database for Prurisol's Phase 2 FDA trial for mild-to-moderate chronic plaque psoriasis has instituted a "Database Soft Lock."

Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
Marketwired - Thu Mar 31, 8:02AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the latest laboratory research on the Company's anti-cancer drug Kevetrin showed that Kevetrin did not inhibit or induce cytochrome P450 enzymes in vitro. Based upon the documented relationship of P450 and certain potential drug-drug interactions, this positive data is central to the planned Phase 2 clinical trial where Kevetrin will be used in a combination therapy for the treatment of ovarian cancer.

Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 14.48 (+0.21), TTPH: 3.91 (+0.02), ADRO: 11.47 (+0.20), EBS: 39.37 (+0.40), UTHR: 103.70 (+1.59), BMY: 71.20 (+0.53), PFNX: 7.99 (-0.03), PIP: 2.23 (+0.03), IBIO: 0.70 (+0.01), OGEN: 0.52 (+0.02)

Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
Marketwired - Thu Mar 17, 9:01AM CDT
Cellceutix (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern.
CELGZ: 1.45 (-0.02)

Technical Insights on Equity Movements -- Research Reports on ALUF Holdings, Vantage Drilling, Cellceutix and Yahoo Japan
ACCESSWIRE - Wed Mar 09, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: ALUF Holdings Inc. (OTC: AHIX), Vantage Drilling Co. (OTC: VTGDF), Cellceutix Corp. (OTC: CTIX) and Yahoo Japan Corp. (OTC: YAHOY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board
Marketwired - Tue Mar 08, 12:23PM CST
Cellceutix Corporation (OTC: CTIX) (the "Company", a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that Dr. Stephen T. Sonis, D.M.D., D.M.Sc., has joined the Cellceutix Scientific Advisory Board. Dr. Sonis is one of the world's foremost experts in the research and clinical treatment of cancer-related oral mucosal toxicities. He currently holds appointments at the Harvard School of Dental Medicine as Professor of Oral Medicine (part-time), and is a Senior Surgeon at the Dana-Farber Cancer Institute and Brigham and Women's Hospital .

Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 77.69 (+0.58), IMGN: 3.34 (+0.02), ARQL: 1.77 (-0.02), LLY: 74.18 (+0.32), GSK: 41.70 (+1.37), ONTY: 1.21 (+0.02), MDVN: 59.50 (+0.17), MRK: 56.31 (+0.42), AZN: 28.53 (+0.95), AVEO: 1.02 (unch), GALE: 2.39 (+0.17), PBYI: 31.85 (+0.63), NVS: 79.29 (+1.38), KPTI: 7.68 (+0.06), XLRN: 34.55 (+0.17), EXEL: 7.65 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 233

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 165

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 311

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 182

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 238

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 162

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 213

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Investment by BrainsWay to Enhance Mental Health Solutions

Updated Category News Views 247

BrainsWay's Expansion Plans and Strategic Investment This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home. Neurolief’s breakthrough Proliv™Rx device is pending Premarket Approval from the U.S. FDA, and if granted, it will set a precedent as the first FDA-cleared medical...

Continue Reading
Mary Street Capital: Enhancing Investment Banking Services

Updated Category News Views 300

Mary Street Capital: A New Era in Investment Banking Mary Street Capital has emerged as an innovative investment banking affiliate of Kaufman Rossin, significantly expanding its advisory capabilities. This new venture focuses on addressing the unique needs of family- and founder-owned businesses, particularly those in the middle market that have often felt overlooked by...

Continue Reading
Fluorine-18 Market Growth Driven by Cancer Diagnosis Demand

Updated Category News Views 169

Fluorine-18 Market Growth Context The global fluorine-18 market is on a notable trajectory of growth, anticipated to reach USD 2.54 billion by 2031 from USD 1.85 billion in 2024. This progression is largely influenced by the increasing incidence of cancer and the expanding utilization of nuclear imaging methodologies. The Role of Fluorine-18 in Medical Diagnostics...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 227

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
Chargeback Rates Increase Dramatically Amid Visa Changes

Updated Category News Views 320

Surge in Chargebacks Signals Major Industry Changes CLEVELAND — The payments industry is witnessing a seismic shift, with chargebacks soaring by an astonishing 222% year over year. This significant rise has impacted various sectors, including eCommerce, travel, subscription services, and healthcare. Understanding Visa's VAMP Program As Visa introduces its new Acquirer...

Continue Reading